Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 2100 West Loop S Ste 900 HOUSTON TX 77027-3522 |
Tel: | 1-833-4758247 |
Website: | https://cnspharma.com |
IR: | See website |
Key People | ||
John Michael Climaco Chief Executive Officer, Director | Christopher S. Downs Chief Financial Officer | Donald H. Picker Chief Science Officer | Sandra L. Silberman Chief Medical Officer |
Business Overview |
CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system (CNS). The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is in development for the treatment of a number of serious brain and CNS oncology indications, including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. In addition, the Company is advancing the development of its WP1244/WP1874 drug technology, which utilizes anthracycline and distamycin-based scaffolds to create small molecule agents. The Company is also evaluating the use of WP1244/WP1874 in the treatment of other primary brain and central nervous system cancers, as well as cancers metastatic to the brain including pancreatic, ovarian, and lymphomas. |
Financial Overview |
For the fiscal year ended 31 December 2023, CNS Pharmaceuticals Inc revenues was not reported. Net loss increased 23% to $18.9M. Higher net loss reflects Research and development increase of 52% to $14.1M (expense), Interest expense increase of 96% to $14K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$11.22 to -$5.00. |
Employees: | 3 as of Apr 1, 2024 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $1.92M as of Dec 31, 2023 |
Annual revenue (TTM): | $0.00M as of Dec 31, 2023 |
EBITDA (TTM): | -$18.86M as of Dec 31, 2023 |
Net annual income (TTM): | -$18.85M as of Dec 31, 2023 |
Free cash flow (TTM): | -$14.14M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 10,634,932 as of Apr 1, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |